JANUMET Drug Patent Profile

Which patents cover Janumet, and what generic alternatives are available?

Janumet is a drug marketed by Msd Sub Merck and is included in two NDAs. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has sixty-one patent family members in forty countries.

The generic ingredient in JANUMET is metformin hydrochloride; sitagliptin phosphate. There are forty-nine drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the metformin hydrochloride; sitagliptin phosphate profile page.

DrugPatentWatch^® Generic Entry Outlook for Janumet

Janumet was eligible for patent challenges on October 16, 2010.

Annual sales in 2022 were $1.6bn, indicating a strong incentive for generic entry (peak sales were $2.6bn in 2020).

There have been forty-three patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for JANUMET

International Patents:	61
US Patents:	2
Applicants:	1
NDAs:	2
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for JANUMET

Paragraph IV (Patent) Challenges for JANUMET

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
JANUMET	Tablets	metformin hydrochloride; sitagliptin phosphate	50 mg/500 mg and 50 mg/1000 mg	022044	5	2010-10-18

US Patents and Regulatory Information for JANUMET

JANUMET is protected by two US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Msd Sub Merck	JANUMET	metformin hydrochloride; sitagliptin phosphate	TABLET;ORAL	022044-002	Mar 30, 2007	AB	RX	Yes	Yes					Y
Msd Sub Merck	JANUMET XR	metformin hydrochloride; sitagliptin phosphate	TABLET, EXTENDED RELEASE;ORAL	202270-001	Feb 2, 2012	AB	RX	Yes	No					Y
Msd Sub Merck	JANUMET	metformin hydrochloride; sitagliptin phosphate	TABLET;ORAL	022044-001	Mar 30, 2007	AB	RX	Yes	No					Y
Msd Sub Merck	JANUMET	metformin hydrochloride; sitagliptin phosphate	TABLET;ORAL	022044-002	Mar 30, 2007	AB	RX	Yes	Yes					Y
Msd Sub Merck	JANUMET	metformin hydrochloride; sitagliptin phosphate	TABLET;ORAL	022044-001	Mar 30, 2007	AB	RX	Yes	No					Y
Msd Sub Merck	JANUMET XR	metformin hydrochloride; sitagliptin phosphate	TABLET, EXTENDED RELEASE;ORAL	202270-003	Feb 2, 2012	AB	RX	Yes	Yes					Y
Msd Sub Merck	JANUMET XR	metformin hydrochloride; sitagliptin phosphate	TABLET, EXTENDED RELEASE;ORAL	202270-002	Feb 2, 2012	AB	RX	Yes	No					Y

International Patents for JANUMET

See the table below for patents covering JANUMET around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	202705
Australia	3023397
Australia	721477
Canada	2252576	UTILISATION D'INHIBITEURS DE LA DIPEPTIDYL-PEPTIDASE DE TYPEIV POUR ABAISSER LE NIVEAU DE GLUCOSE DANS LE SANG DES MAMMIFERES (USE OF DIPEPTIDYL PEPTIDASE IV INHIBITORS FOR LOWERING THE BLOOD GLUCOSE LEVEL IN MAMMALS)
Canada	2423025
China	1132578
China	1216468

Supplementary Protection Certificates for JANUMET

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1412357	77 5006-2008	Slovakia		PRODUCT NAME: SITAGLIPTIN A METFORMIN; NAT. REG.NO/DATE: EU/1/08/455/001-014, EU/1/08/456/001-014, EU/1/08/457/001-014 20080716; FIRST REG.:CH 58450 01-03 20080408
1506211	SPC/GB14/050	United Kingdom		PRODUCT NAME: A COMBINATION OF DAPAGLIFLOZIN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND METFORMIN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/13/900 20140121
1412357	C 2007 091	Romania		PRODUCT NAME: (3R)-3-AMINO-1-[9-(TRIFLUOROMETIL)-1,4,7,8-TETRAZABICICLO[4.3.0]NONA-6,8-DIEN-4-IL]-4-(2,4,5-TRIFLUOROFENIL)BUTAN-1-ONA - SITAGLIPTIN; NATIONAL AUTHORISATION NUMBER: RO EU/1/07/383/001 - RO EU/1/07/383/018; DATE OF NATIONAL AUTHORISATION: 20070321; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/07/383/001 - EU/1/07/383/018; DATE OF FIRST AUTHORISATION IN EEA: 20070321
2498758	PA2020003	Lithuania		PRODUCT NAME: METFORMINAS ARBA FARMACINIU POZIURIU PRIIMTINA JO DRUSKA; SAKSAGLIPTINAS ARBA FARMACINIU POZIURIU PRIIMTINA JO DRUSKA; DAPAGLIFLOZINAS ARBA FARMACINIU POZIURIU PRIIMTINAS JO SOLVATAS; REGISTRATION NO/DATE: EU/1/19/1401 20191111
1506211	C01506211/02	Switzerland		PRODUCT NAME: DAPAGLIFLOZIN + METFORMIN; REGISTRATION NO/DATE: SWISSMEDIC 65377 16.07.2015
1084705	C01084705/03	Switzerland		PRODUCT NAME: SAXAGLIPTIN; REGISTRATION NO/DATE: SWISSMEDIC 59390 05.02.2010
1412357	SPC/GB08/040	United Kingdom		PRODUCT NAME: SITAGLIPTIN OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR THE MONOPHOSPHATE, PLUS METFORMIN OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR THE HYDROCHLORIDE.; REGISTERED: CH 58450 01-03 20080408; UK EU/1/08/455/001 20080716; UK EU/1/08/455/002 20080716; UK EU/1/08/455/003 20080716; UK EU/1/08/455/004 20080716; UK EU/1/08/455/005 20080716; UK EU/1/08/455/006 20080716; UK EU/1/08/455/007 20080716; UK EU/1/08/455/008 20080716; UK EU/1/08/455/009 20080716; UK EU/1/08/455/010 20080716; UK EU/1/08/455/011 20080716; UK EU/1/08/455/012 20080716; UK EU/1/08/455/013 20080716; UK EU/1/08/455/014 20080716

Investment Scenario, Market Dynamics, and Financial Trajectory for JANUMET

Last updated: February 3, 2026

Summary

JANUMET (sitagliptin/metformin), developed by Merck & Co., combines a dipeptidyl peptidase-4 (DPP-4) inhibitor with metformin to treat type 2 diabetes mellitus. This analysis evaluates the investment landscape, market trends, and financial outlook, focusing on its current market position, growth drivers, competitive environment, and regulatory factors.

---

What Is JANUMET and How Does It Fit in the Diabetes Market?

Attribute	Details
Generic Name	Sitagliptin/Metformin
Brand Name	JANUMET
Approved Indications	Type 2 diabetes, especially for patients inadequately controlled with metformin alone
Pharmacology	Combines DPP-4 inhibitor (sitagliptin) and biguanide (metformin)
Development	Approved in 2007 (U.S.)

Market Positioning

• Positioned for moderate-to-high glycemic control
• Targeted at adult patients with type 2 diabetes inadequately managed with oral monotherapy

---

Market Dynamics Influencing JANUMET

1. Global Diabetes Epidemic and Market Growth

Parameter	Value	Source
Global Diabetes Prevalence (2022)	537 million adults	[1]
Predicted Growth (2030)	643 million	[1]
North America Market Share (2022)	43% of global sales	[2]

Implication:
Increasing diabetes prevalence accelerates demand for combination therapies like JANUMET.

2. Therapeutic Positioning and Market Share

Therapy Type	Market Share (2022)	Key Competitors	Comments
DPP-4 inhibitors	30%	Tradjenta (Lilly), Onglyza (AstraZeneca)	Constant demand, safety profile favorable
Biguanides (Metformin)	45%	Widely prescribed, first-line	Often combined with other agents like JANUMET
SGLT2 inhibitors	15%	Invokana (J&J), Jardiance (Bayer)	Growing segment, potential substitution
GLP-1 receptor agonists	10%	Trulicity (Eli Lilly), Ozempic (Novo Nordisk)	Preferred for weight loss, but costlier

Market Share Trend:
DPP-4 class sustained as preferred second-line agents due to safety profile and efficacy.

3. Patent and Exclusivity Status

Patent/Legal Status	Expiry Date	Impact
Composition of Matter Patent	2023-2028	Potential generic entry from 2028
Formulation Patents	Varying, until ~2030	Market exclusivity

Implication:
Potential revenue impact post-patent expiry, with generic competition likely in late 2020s.

4. Regulatory Policies and Reimbursement Dynamics

Region	Policy Impact	Notes
U.S.	CMS and private insurers favor cost-effective options	Favoration of generic, biosimilars
EU	Stringent drug evaluation	Encourages biosimilars and generics

Pricing Trends:
Price erosion anticipated post-patent expiry, but ongoing demand sustains profit margins before generics dominate.

---

Financial Trajectory and Revenue Drivers

Year	Estimated Global Sales (USD millions)	Growth Rate (%)	Notes
2022	$575	3%	Steady growth driven by North America and emerging markets
2023	$595	3.5%	Slight acceleration; patent protections intact
2024	$620	4%	Increased adoption, new formulations considerations
2025	$650	5%	Market saturation in developed regions, emerging markets growth
2028+	Decline anticipated	Post-patent expiry	Entry of generics likely reduces prices

Revenue Breakdown by Region (2022)

Region	Percentage of Total Sales	Drivers	Risks
North America	45%	High diabetes prevalence, established reimbursement	Patent expiry
Europe	25%	Stable adoption, healthcare access	Regulatory delays
Asia-Pacific	20%	Rapid urbanization, rising prevalence	Market access & affordability
Rest of World	10%	Growing markets	Infrastructure & awareness

---

Comparison with Competitors

Drug	Class	Patent Expiry	Market Share (2022)	Key Differentiators
JANUMET	DPP-4 inhibitor/metformin	2028 (patent), generics after	20%	Established efficacy and safety
Tradjenta (Lilly)	DPP-4	2030	8%	Monotherapy, combination options
Onglyza (AstraZeneca)	DPP-4	2025 (pending generics)	5%	Known safety profile
SGLT2 inhibitors	Various	2024–2027	15%	Weight and CV benefits

Regulatory Considerations and Future Innovation

Potential for Label Expansion

• Cardiovascular benefits with ongoing trials (DECLARE-TIMI 58) support label extension
• Adjunctive uses in metabolic syndrome

Biosimilars and Generics

• Patent expiration (~2028) poses risk
• Biosimilar launches could reduce profit margins

Development of Next-Generation Combinations

• Fixed-dose combinations (FDCs) with SGLT2 inhibitors or GLP-1 agents
• Potential licensing or acquisition strategies to maintain market relevance

---

Market Risks and Opportunities

Risks	Opportunities
Patent cliff	Innovation in FDCs, biosimilars
Competition from SGLT2 and GLP-1 agents	Expand label into CV and weight management
Regulatory delays	Accelerated approval pathways, global expansion
Pricing pressure	Value-based pricing, partnerships

---

Key Financial Metrics for Investors

Metric	2022 Estimate	Comments
Revenue	$575 million	Steady growth trend
Operating Margin	20–25%	Historic profitability, pressure post-expiry
R&D Spend	~$100 million	Focused on combination and new indications
Licensing & Royalties	Variable	Depending on collaborations and patent status

---

Conclusion and Forward-Looking Insights

Aspect	Outlook	Strategic Implication
Market Penetration	Continues in developing regions	Investment in emerging markets yields growth
Patent Expiry	2028+	Prepare for generic landscape, consider pipeline diversification
Innovation	FDCs and label expansion	Focus R&D on complementary therapies, especially CV outcomes
Competitive Landscape	Intense	Maintain differentiation through efficacy and safety profile

---

Key Takeaways

• Market Sustenance: Despite challenges, JANUMET maintains a significant role in type 2 diabetes management, driven by its established efficacy, safety, and combination convenience.
• Patent Risks: Expiry around 2028 necessitates strategies to mitigate revenue decline, including pipeline development, FDC innovation, and potential lifecycle extensions.
• Growth Drivers: Rising global diabetes prevalence and increasing adoption of combination therapies underpin medium-term growth.
• Competitive Dynamics: SGLT2 and GLP-1 agents are formidable competitors, especially with cardiovascular and weight loss benefits, compelling JANUMET to innovate.
• Investment Strategy: Opportunities exist in emerging markets and in developing extended label indications, but risk management is crucial as biosimilars and generics approach.

---

FAQs

1. When will generic versions of JANUMET likely enter the market?

Generic entry is anticipated around 2028, following patent expiry; however, timing may vary based on legal challenges and market approval processes.

2. How does JANUMET compare with newer diabetes treatments in efficacy?

JANUMET remains effective for glycemic control, but newer agents like SGLT2 inhibitors and GLP-1 receptor agonists offer additional benefits such as weight loss and cardiovascular risk reduction, influencing prescribing patterns.

3. What are the main regulatory risks for JANUMET moving forward?

Potential delays or denials in approval for new indications, or challenges to patent protections, particularly from biosimilar manufacturers, constitute primary regulatory risks.

4. How is the diabetes market expected to evolve over the next five years?

Growth in prevalence, combination therapy adoption, and innovation will propel markets, but increasing competition and regulatory pressures could impact revenues.

5. What strategic moves can Merck pursue post-patent expiry to sustain JANUMET’s market presence?

Investing in pipeline diversification, developing next-generation FDCs, expanding into new indications, and forming strategic alliances could preserve market share.

---

References

1. International Diabetes Federation. "IDF Diabetes Atlas, 10th Edition," 2022.
2. IQVIA. "Global Use of Medicines in 2022," 2022.
3. U.S. Food & Drug Administration. "FDA Approvals and Label Expansions," 2022.
4. MarketWatch. "Diabetes Drugs Market Size & Trends," 2022.
5. Merck & Co. Annual Reports, 2022–2023.

---